News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ThromboGenics NV (TBGNF)'s JETREA® Granted EU Approval for Vitreomacular Traction (VMT), Including When Associated With Macular Hole of Diameter Less Than or Equal to 400 Microns


3/15/2013 10:05:00 AM

LEUVEN, Belgium, March 15, 2013 -- /PRNewswire/ --EU approval of JETREA® triggers a €45 million milestone payment from Alcon.

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that the European Commission has approved JETREA® (ocriplasmin) in the European Union. JETREA® is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. The EU approval triggers a €45 million milestone payment to ThromboGenics from its partner Alcon. The first sale of JETREA® in the EU by Alcon will trigger a further €45 million milestone payment to ThromboGenics.


Read at Sacramento Bee


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES